AEON Biopharma, Inc. Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired
AEON Biopharma, Inc. (AEON) reported Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired of $348.00 million for the 5-month period ending 2023-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Notes
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired · last filed 2025-03-24
- 2023-12-31: Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 5 month $348.00M.
- 2023-09-30: Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 2 month $348.00M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 2 month | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 5 month |
|---|---|---|
| 2023-12-31 | $348.00M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $348.00M 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |